References

  1. Salimi A, Pourahmad J. Measurement of Mitochondrial Toxicity Parameters in Embryonic Hippocampus.Methods Mol Biol. 2018;1797:537-44.
  2. Patananan AN, Sercel AJ, Teitell MA. More than a powerplant: the influence of mitochondrial transfer on the epigenome. Curr Opin Physiol. 2018 ;3:16-24.
  3. Thar R, Kühl M. Propagation of electromagnetic radiation in mitochondria? J Theoretical Biology. 2004;230(2):261-70.
  4. Birk AV, Chao WM, Bracken C, Warren JD, Szeto HH. Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. Br J Pharmacol. 2014;171(8):2017-28.
  5. Chicco AJ, Sparagna GC. Role of cardiolipin alterations in mitochondrial dysfunction and disease. Am J Physiol Cell Physiol. 2007;292(1):C33-44.
  6. Rahman J, Rahman S. Mitochondrial medicine in the omics era. Lancet. 2018 Jun 11. pii: S0140-6736(18)30727-X. doi: 10.1016/S0140-6736(18)30727-X. [Epub ahead of print]
  7. Bayeva M, Gheorghiade M, Ardehali H. Mitochondria as a therapeutic target in heart failure. J Am Coll Cardiol. 2013;61(6):599-610.
  8. Chen M, Liu B, Gao Q, Zhuo Y, Ge J. Mitochondria-targeted peptide MTP-131 alleviates mitochondrial dysfunction and oxidative damage in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2011;52(10):7027-37.
  9. Reddy PH, Reddy TP. Mitochondria as a therapeutic target for aging and neurodegenerative diseases. Curr Alzheimer Res. 2011;8(4):393-409.
  10. Pfeffer G, Chinnery PF. Diagnosis and treatment of mitochondrial myopathies. Ann Med. 2013;45(1):4-16.
  11. Suomalainen A, Battersby BJ. Mitochondrial diseases: the contribution of organelle stress responses to pathology. Nat Rev Mol Cell Biol. 2018;19(2):77-92.
  12. Ahuja AS. Understanding mitochondrial myopathies: a review. PeerJ. 2018;6:e4790.
  13. Karaa A, Haas R, Goldstein A, Vockley J, Weaver WD, Cohen BH. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018;90(14):e1212-e1221
  14. Szeto HH, Liu S, Soong Y, et al. Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury. J Am Soc Nephrol. 2011;22: 1041-52.
  15. Siegel M, Kruse S, Percival J, et al. Mitochondrial-targeted peptide rapidly improves mitochondrial energetic and skeletal muscle performance in aged mice. Aging Cell. 2013;12:763-771.
  16. Birk A, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 reenergizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24:1250-61.
  17. Brown DA, Hale SL, Baines CP, et al. Reduction of early reperfusion injury with the mitochondria-targeting peptide Bendavia. J Cardiovasc Pharmacol. 2014;19:121-32.
  18. Stauffer B, Sparagna G, Chau S, et al. MTP131, a cardiolipin targeting peptide,improves mitochondrial activity in the failing human heart. Eur J Heart Fail Abstr Suppl 2016;18:289.
  19. Eirin A, Ebrahimi B, Zhang X, et al. Mitochondrial protection restores renal function in swine atherosclerotic renovascular disease. Cardiovasc Res. 2014;103: 461-72.
  20. Gorman GS, Schaefer AM, Ng Y, Gomez N, Blakely EL, Alston CL, et al. Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Ann Neurol. 2015;77(5):753-9.
  21. MMPOWER-3 Clinical Trial Information. Available at https://clinicaltrials.gov/ct2/show/NCT03323749. Accessed June 21, 2018.
  22. Roberts AE, Nixon C, Steward CG, Gauvreau K, Maisenbacher M, Fletcher M, et al. The Barth syndrome registry: distinguishing disease characteristics and growth data from a longitudinal study. Am J Med Genet A. 2012;158A:2726-32.
  23. Wortmann SB, Kluijtmans LA, Engelke UF, Wevers RA, Morava E. The 3-methylglutaconic acidurias: what’s new? J Inherit Metab Dis. 2012;35(1):13-22.
  24. Clarke SL, Bowron A, Gonzalez IL, Groves SJ, Newbury-Ecob R, Clayton N, et al. Barth syndrome. Orphanet J Rare Dis. 2013;8:23.
  25. TAZPOWER Clinical Trial Information. Available at https://clinicaltrials.gov/ct2/show/NCT03098797. Accessed June 21, 2018.
  26. Jurkute N, Yu-Wai-Man P. Leber hereditary optic neuropathy: bridging the translational gap. Curr Opin Ophthalmol. 2017;28(5):403-09.
  27. LHON Global. How rare is LOHN? Page updated September 2015. Accessed June 16, 2018 at https://lhon.global/how-rare-is-lhon/.
  28. Ratican SE, Osborne A, Martin KR. Progress in Gene Therapy to Prevent Retinal Ganglion Cell Loss in Glaucoma and Leber’s Hereditary Optic Neuropathy. Neural Plast. 2018;2018:7108948.
  29. ReSIGHT Clincal Trial Information. Available at https://clinicaltrials.gov/ct2/show/NCT02693119. Accessed June 21, 2018.
  30. Ratnapriya R, Chew EY. Age-related macular degeneration-clinical review and genetics update. Clin Genet. 2013;84(2):160-6.
  31. Hernández-Zimbrón LF, Zamora-Alvarado R, Ochoa-De la Paz L, Velez-Montoya R, Zenteno E, Gulias-Cañizo R, et al. Age-related macular degeneration: new paradigms for treatment and management of AMD. Oxid Med Cell Longev. 2018;2018:8374647
  32. Klein R, Chou CF, Klein BE, Zhang X, Meuer SM, Saaddine JB. Prevalence of age-related macular degeneration in the US population. Arch Ophthalmol. 2011;129(1):75-80.
  33. Congdon N, O’Colmain B, Klaver CC, Klein R, Muñoz B, Friedman DS, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Opthalmol. 2004;122(4):477-85.
  34. ReCLAIM Clincial Trial Information. Available at https://clinicaltrials.gov/ct2/show/NCT02848313. Accessed June 21, 2018.
  35. Chinnery PF. Mitochondrial Disorders Overview. 2000 Jun 8 [Updated 2014 Aug 14]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1224/. Accessed June 16, 2018.
  36. Noble P. “Denis Archibald Leigh”. Psychiatric Bulletin. 2018;22 (10):648-9.
  37. Barth PG, Scholte HR, Berden JA, Vanderkleivanmoorsel JM, Luythouwen IEM, Vantveerkorthof ET, et al. An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes. J Neurol Sci. 1983;62: 327-55.